Moderna, Inc. — Director's Dealing 2020

Nov 10, 2020

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Moderna, Inc. (MRNA)
CIK: 0001682852
Period of Report: 2020-11-09

Reporting Person: Zaks Tal Zvi (Chief Medical Officer)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2020-11-09	Common Stock	M	5000	$12.21	Acquired	5000	Direct
2020-11-09	Common Stock	M	10000	$19.15	Acquired	15000	Direct
2020-11-09	Common Stock	S	1925	$76.51	Disposed	13075	Direct
2020-11-09	Common Stock	S	4971	$77.47	Disposed	8104	Direct
2020-11-09	Common Stock	S	6404	$78.37	Disposed	1700	Direct
2020-11-09	Common Stock	S	1400	$79.31	Disposed	300	Direct
2020-11-09	Common Stock	S	300	$80.11	Disposed	0	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2020-11-09	Stock Option (Right to Buy)	$12.21	M	5000	Disposed	2027-10-03	Common Stock (5000)	Direct
2020-11-09	Stock Option (Right to Buy)	$19.15	M	10000	Disposed	2026-08-10	Common Stock (10000)	Direct

Footnotes

F1: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on March 13, 2020.

F2: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $75.90 to $76.85. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.

F3: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $76.94 to $77.94. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.

F4: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $77.95 to $78.88. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.

F5: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $78.96 to $79.85. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.

F6: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $80.07 to $80.16. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.

F7: 229,358 of the options will vest over 4 years (25% on the first anniversary of the grant date of October 3, 2017, then quarterly for the next 3 years). 137,614 of the options will vest over 5 years (25% on the second anniversary of the grant date of October 3, 2017, then quarterly for the next 3 years). 91,743 of the options will vest over 6 years (25% on the third anniversary of the grant date of October 3, 2017, then quarterly for the next 3 years).

F8: This option is fully vested and exercisable.